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The aim of the present study was to evaluate the effectiveness of two consecutive nonrandomised treatment programs applied
between 1989 and 1999 at the Istituto Nazionale Tumori of Milan in an unselected cohort of 59 children over the age of one with
stage 4 neuroblastoma. Both treatment programs consisted of two phases, the induction of the remission phase and the
consolidation phase. The induction of the remission phase consisted of intensive chemotherapy, and remained the same throughout
the study period. The consolidation phase consisted of sequential hemi-body irradiation (HBI) (10Gy per session, 6 weeks apart) in
the first period (1988–June 1994) and sequential high-dose cyclophosphamide, etoposide, mitoxantroneþ L-PAM and autologous
haemopoietic stem cell transplantation in the second (July 1994–1999). Intention-to-treat analysis revealed a significantly better
outcome for patients treated with the second program, the 5-year event-free survival probability being 0.12 for program 1 and 0.31
for program 2 (P¼0.03). This finding led us to conclude that sequential HBI is useless as consolidation treatment. The high-dose
chemotherapy adopted in the second program enabled a proportion of patients to obtain long-term survival but, since the clinical
results remain unsatisfactory, new treatment strategies are warranted.
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In the past two decades, the prognosis for patients with stage 4
neuroblastoma over the age of 1 year has progressively changed,
with a weak but significant improvement in clinical results
(Goldsby and Matthay, 2004). This slight improvement can be
related to the greater and greater aggressiveness of the treatment:
intensified chemotherapy increases the percentage of clinical
remissions, the introduction of megatherapy helps to eradicate
resistant clones, and the addition of ‘maintenance’ therapy is
expected to control any minimal residual disease (Cheung et al,
1998; Pession et al, 1998; Garaventa et al, 1999; Matthay et al, 1999;
Pinkerton et al, 2000). The use of aggressive surgery and
radiotherapy to the primary tumour site may also contribute to
reducing the risk of local relapse (Kushner et al, 2001; Haas-Kogan
et al, 2003; La Quaglia et al, 2004). Nowadays, the majority of
clinical trials on advanced neuroblastoma are organised according
to the sequence: ‘induction’ of remission with chemotherapy and
local treatment at the primary tumour site, ‘consolidation’ with
megatherapy, and ‘maintenance’ therapy (Matthay et al, 1999;
Berthold and Hero, 2000; De Bernardi et al, 2003). The number of
studies focusing on the impact of each treatment modality within
this arrangement is still limited, however, and the studies on this
issue with a randomised design are rarer still (Ladenstein et al,
1994; Pearson et al, 1994; Matthay et al, 1999; Berthold and Hero,
2000; Pritchard et al, 2005).
In the present study, we describe a mono-institutional
experience of two consecutive nonrandomised treatment programs
comprising an identical induction phase, followed by two different
strategies for the consolidation phase, that is, sequential fractio-
nated hemi-body irradiation (HBI) in the first case and sequential
high-dose chemotherapy plus autologous haemopoietic stem cell
transplantation in the second. Our aim was to explore the impact
of these two strategies on outcome.
PATIENTS AND METHODS
All children over the age of 1 year with previously untreated stage 4
neuroblastoma diagnosed from 1989 to 1999 at the Istituto
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sNazionale Tumori of Milan were prospectively enrolled in the
institutional treatment programs.
Diagnosis, staging and response to therapy were evaluated
according to the International Neuroblastoma Staging System and
the International Neuroblastoma Response Criteria (Brodeur et al,
1993). The diagnosis was based on a histological examination or, in
some cases, on the documentation of an unequivocal bone marrow
infiltration. The initial evaluation included CT or MRI of the
primary tumour, 131-I-mIBG scan, TC-99-MDP scan, bilateral
bone marrow biopsy and aspirate, serum levels of LDH, neuron-
specific enolase and ferritin, and urinary concentrations of
vanylmandelic and homovanillic acids. Response to treatment
was assessed after each of the two steps in the treatment strategy
(induction and consolidation).
During the study period (1989–1999), two different, non-
randomised treatment programs were adopted (Table 1), both
approved by the local Ethical and Scientific Board. The intention
was to treat every new child over the age of one admitted to our
institution with previously untreated stage 4 neuroblastoma. A
stopping rule for toxic deaths was set for both treatment programs.
The first program (program-1), applied between January 1989
and June 1994, consisted of an ‘induction of remission’ phase
with intensive chemotherapy and a ‘consolidation of remission’
phase with sequential fractionated HBI. Briefly, the induction
phase consisted of eight cycles of vincristineþcisplatinumþ
etoposideþepi-adriamycin alternated at 4-week intervals
with vincristineþcisplatinumþetoposideþifosfamide. In each
patient, the doses of all drugs except vincristine had to be scaled
up by 20% at each subsequent cycle if the nadir after the previous
cycle coincided with WBC X1000cumm
 1 and/or platelets
X70000cumm
 1. The doses had to be scaled down by 20% if
the nadir coincided with WBC o1000 and/or platelets
o70000cumm
 1; the minimal doses given were 100%. At 3 weeks
after ending the induction, patients with an objective response
(complete, very good, or partial remission) began the consolida-
tion phase. In program-1, this consisted of two consecutive
sessions of HBI. The upper and lower body halves were irradiated,
with a 6-week interval between the two sessions, using a
fractionated technique described elsewhere (Lombardi et al,
1989): 10Gy, as midplane dose, were delivered in five daily
fractions, 2Gyday
 1, through two lateral opposite portals at a
dosage of 0.2Gymin
 1 by a 15MeV linear accelerator. Program-1
had two aims, that is, to reach an objective response rate higher
than the 60% achieved by the previous treatment program
(Lombardi et al, 1989), and to evaluate the impact of HBI on
clinical outcome.
The second program (program-2) was adopted between July
1994 and December 1999. This program only differed from the
previous one as regards the consolidation phase, which consisted
of a sequence at 3-week intervals of cyclophosphamide 7gsqm
 1,
etoposide 2gsqm
 1, mitoxantrone 60mgsqm
 1þmelphalan
210mgsqm
 1, followed by autologous peripheral blood stem cell
transplantation (Table 1). Stem cells were collected from
peripheral blood using G-CSF 10mgkg
 1day
 1 as of day 4 after
administering cyclophosphamide up until the day of leuka-
pheresis. If this target was not reached after cyclophosphamide
(at least 3 10e6 CD34þcellskg
 1), an additional leukapheresis
was performed after etoposide, using G-CSF at the same dose as
after cyclophosphamide. The aim of program-2 was to evaluate the
impact of this consolidation phase on clinical outcome.
In both programs 1 and 2, surgical resection of the primary
tumour was on an individual basis and considered as part of the
induction of remission phase. In addition, ‘local’ treatment with
radiotherapy was not specified by the treatment plan, and no
further treatment was planned after the end of the consolidation
phase. Supportive care policies did not change substantially during
the study period, with the exception of the use of G-CSF, from
1996 onwards, in cases of febrile neutropenia and documented
infection.
In the present study, we describe our mono-institutional
experience with the two programs described above. The primary
goal of the present study was to assess event-free survival (EFS)
and survival (S) probabilities for the two groups of patients
enrolled on programs 1 and 2 using an intention-to-treat analysis.
Event-free survival was calculated from the first day of treatment
up until progression or relapse, or death due to toxicity. Survival
was calculated from the first day of treatment until death. EFS and
S distributions were estimated using the Kaplan–Meier method,
and compared with the log-rank test. To evaluate the homogeneity
of the characteristics of the patients enrolled in programs 1 and 2,
the frequency distribution of different variables in the two
groups was compared using the w
2 test for: sex, age, site of
primary tumour, LDH level, serum ferritin, serum NSE, AVM/HVA
dosage, cumulative % of drug dosages delivered during induction
(X120 vs o120% of the initial dose), surgery on the primary
tumour site.
RESULTS
All 59 consecutive children over the age of 1 year with stage 4
neuroblastoma at onset observed at the Istituto Nazionale Tumori
of Milan during the study period were enrolled. In total, 25 joined
program-1 and 34 joined program-2. In all cases, the diagnosis,
treatment and follow-up were completed at the Istituto Nazionale
Tumori.
Table 1 Treatment programs for stage 4 neuroblastoma over the age of 1 year, 1989–1999
Consolidation phase
Induction phase Program-1 (January 1989–June 1994)
Course A B A B A B A B S 1st HBI 2nd HBI
k k k kkkkkk k k
Week 04 71 01 31 61 92 2 2 6 3 2
Program-2 (July 1994–December 1999)
HDCTX HDVP16 MGT+autograft
kk k
26 29 32
Course A¼vincristine day 1; etoposide+cisplatinum+epirubicin days 1–4. Course B¼vincristine day 1; etoposide+cisplatinum+ifosfamide days 1–4. S¼surgery on the primary
tumour site, on individual basis. HBI¼hemi-body irradiation. HDCTX¼high-dose cyclophosphamide; HDVP16¼high-dose etoposide; MGT+autograft¼high-dose
mitoxantrone (day  5)+melphalan (day  2)+autologous stem cell transplantation (day 0).
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shown in Table 2. The M/F ratio was 1.3, and the median age at
diagnosis was 3 years (range 1–18). The site of primary tumour
was the retroperitoneum/adrenal gland in the majority of patients
(85%). Skeleton and bone marrow were the most frequent sites of
metastases (85 and 72%, respectively), followed by distant lymph
nodes (37%), liver (14%), orbitae (14%), central nervous system
(8%) and lungs (3%). The distribution of clinical variables at onset,
the drug doses given, the number of patients who underwent
surgery on the primary tumour site (Table 2), and the response to
induction treatment (Table 3) were similar in the two groups.
All patients received at least two cycles of induction therapy and
were evaluable for response. The maximal response during
induction was as follows: complete remission, 10; very good
partial remission, 10; partial remission, 33; no response (stable
disease or progression of disease) 6. In all, the percentage of
responders was 89%. Six of the patients with partial remission
experienced progression of disease during the induction treatment,
however, so 47 patients concluded the induction phase and entered
the consolidation phase. Two additional patients – one after the
first HBI session in program-1, and one after high-dose VP16 in
program-2 – had progression of disease during the consolidation
phase. Thus, 45 patients completed the entire treatment plan, 18
out of 25 (72%) in program-1 and 27 out of 34 (79%) in program-2.
Consolidation treatment determined a further response in two out
of 19 (11%) after HBI in program-1 and in 16 out of 27 (59%) after
high-dose therapy in program-2 (Table 3). As for the timing of the
treatments, 62% of cases concluded the treatment program as
scheduled, or with a delay o15 days, while the remaining 38% of
cases had an overall delay X15 days (range 15–45). The
percentage of cases with a delay of the timing of the treatment
in program-1 and program-2 were superimposable (data not
shown). For both programs, acute toxicity was mainly haemato-
logical. There were no toxic deaths or treatment interruptions due
to severe adverse events.
Among the patients who concluded the treatment program, 31
relapsed a median 16 months after diagnosis (range 9–66). The
relapse pattern was: metastatic spread, 21 (68%); metastatic spread
plus local relapse, eight (26%); isolated local relapse, two (6%).
None of the patients with nonresponse or progression of disease
survived after second-line therapy. In all, 46 out of 59 patients died
(22 in program-1 and 24 in program-2). The median follow-up for
the entire series at the time of the current analysis (as at June 2004)
was 62 months (range 51–164). The 5-year EFS and 5-year S
probability for the entire series was 0.18 and 0.25, respectively
(Figure 1). Analysing the outcome according to the treatment
program adopted revealed a significant difference between the two:
the 5-year EFS probability was 0.12 for program-1 and 0.31 for
program-2 (P¼0.03); the 5-year S probability was 0.12 for
program-1 and 0.35 for program-2 (P¼0.03) (Figure 2).
DISCUSSION
Total-body irradiation (TBI) has been widely used in the treatment
of advanced NB, mainly as a consolidation strategy, followed by
haemopoietic stem cell transplantation (Ladenstein et al, 1994;
Matthay et al, 1999). Alternative methods of TBI had also been
applied in NB, consisting of cyclic low-dose TBI (D’Angio and
Evans, 1983) or sequential HBI in combination with chemotherapy
Table 2 Clinical characteristics at onset and treatment given before
consolidation treatment
Program-1 Program-2
Total¼25 % Total¼34 %
Sex
Male 14 56 19 56
Female 11 44 15 44
Age ranges (months)
12–24 9 36 11 32
25–216 16 64 23 68
Primary tumour site
Retroperitoneum/adrenal gland 22 88 27 79
Other sites 3 12 7 21
Bone marrow infiltration
Absent 6 24 8 23
Present 19 76 23 77
Bone metastases
Absent 5 20 4 12
Present 20 80 30 88
LDH (56 evaluated)
o2n 93 71 23 7
X2n 15 63 20 63
NSE (54 evaluated)
o100ngml
 1 10 43 12 39
X100ngml
 1 13 57 19 61
Ferritin (47 evaluated)
o143ngml
 1 52 5 93 3
X143ngml
 1 15 75 18 67
VMA/HVA ratio (44 evaluated)
o1 1 06 21 86 4
X1 6 38 10 36
Mean dose of chemotherapy during induction phase
o120% 11 58 19 70
X120% 8 42 9 30
Surgery on primary tumour site
No 17 84 19 71
Yes 2 16 9 29
Abbreviations: LDH¼lactate dehydrogenase; NSE¼neuron-specific enolase;
VMA¼vanylmandelic acid; HVA¼homovanillic acid. 47 patients who concluded
the induction phase. The distribution of clinical variables at onset, the drug doses
given, the number of patients who underwent surgery on the primary tumour site
were similar in the two groups (P: NS for all variables).
Table 3 Response to therapy by treatment program
Program-1 Program-2
No. of patients % No. of patients %
After induction phase (59 patients)
Complete remission 4 16 6 18
Very good partial remission 5 20 5 15
Partial remission 11 44 16 47
No response/progression 5 20 7 20
After consolidation phase (47 patients)
Complete remission 4 20 16 59
Very good partial remission 7 35 8 30
Partial remission 8 40 2 7
No response/progression 1514
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or HBI and concomitant chemotherapy were similar to those
obtainable by chemotherapy alone, and were complicated by a
more severe toxicity, so these modalities were abandoned.
Sequential HBI in advanced NB was also used at the Istituto
Nazionale Tumori of Milan, but in a different way, that is, HBI was
given as a consolidation strategy after the remission phase, and the
results of this experience suggested that fractionated HBI for
consolidation after chemotherapy might have a favourable effect
on outcome (Lombardi et al, 1989). The promising results of this
experience led us to design the program-1 described in the present
study in 1989, in which the induction phase with a combination of
five drugs in rising doses led to a response rate of 89%, a result
comparable with those obtained in other trials (Berthold and Hero,
2000; Pinkerton et al, 2000; Goldsby and Matthay, 2004). Despite
the use of intensive chemotherapy, no toxic deaths were
encountered and none of the patients had to interrupt the
treatment due to toxicity. The clinical outcome of patients treated
with program-1 remained poor, however, since the majority had
recurrent disease within 24 months of diagnosis despite the high
percentage of responders in the induction phase. This led us to
conclude that sequential HBI was useless as a consolidation
treatment in advanced NB.
Program-2 was designed to try to improve on the results
obtained by program-1 by modifying the consolidation phase. Our
aim was to explore the role of high-dose sequential cyclophos-
phamide, etoposide and mitoxantroneþmelphalan in erasing
residual neoplastic clones proving resistant to the induction phase.
Using this schedule, different drugs known to be active in NB were
used, with the exception of mitoxantrone, whose activity in NB had
been demonstrated in vitro (Fulda et al, 1995) but had never been
explored in vivo (Kushner et al, 1990; Pinkerton, 1991; Berthold
and Hero, 2000). The consolidation treatment adopted in program-
2 led us to support the activity of megatherapy in advanced NB, on
the grounds of two arguments. The first is the further response
obtained with high-dose therapy after the induction therapy in a
consistent number of cases – notably higher than the response
obtained with HBI. The second is the 5-year survival probability of
patients treated with program-2, which was 0.35 – significantly
better than for patients treated with program-1.
In the present study, only a small number of patients had
surgery on the primary tumour site so we cannot draw any
conclusions concerning the impact of a ‘local’ treatment on the
survival probability in this series. Since surgery and radiotherapy
on the primary tumour site have been shown to contribute
to controlling local relapses in stage 4 NB (Kushner et al, 2001;
Haas-Kogan et al, 2003; La Quaglia et al, 2004), it may be that
adding a ‘local’ treatment with surgery plus radiotherapy in an
extended way to program-2 might further improve the results we
obtained.
We are naturally aware that the limited number of patients
enrolled over a lengthy study period and the mono-institutional
setting could constitute a bias of our study, and that the statistical
results should be interpreted with caution as there might be
additional unforseen bias due to the nonrandom design of the
treatment programs applied. Furthermore, the possibility that the
use of G-CSF could have concurred in the better outcome of
program-2 cannot be excluded for certainty. In fact, in the two
programs no differences were recorded as to the timing of drug
administration schedule and no treatment discontinuation due to
acute severe toxicity were recorded in either program. This study
included an unselected cohort of patients, the results are described
as intention-to-treat, and the survival probability is calculated on
the strength of a long follow-up. The use of the same induction
treatment throughout the study and the comparable clinical
characteristics of the two groups of patients strongly suggest the
superiority of the therapeutic results of consolidation treatment
with sequential high-dose chemotherapy and autologous stem cell
transplantation. Our experience can be added to the limited
number of other papers comparing different consolidation
strategies after a common induction phase, thus making the
results of these strategies fully comparable. These studies evaluated
megatherapy vs continuing intensive chemotherapy (Matthay et al,
1999), or maintenance chemotherapy (Berthold et al, 1990; Castel
et al, 2001), or no treatment (Pritchard et al, 2005). Combined with
the other experiences including megatherapy, they reliably support
the conviction that this consolidation treatment modality offers an
advantage in terms of survival probability (McCowage et al, 1995;
Kushner et al, 2001; Frappaz et al, 2002; Kaneko et al, 2002; Kletzel
et al, 2002; De Bernardi et al, 2003).
In spite of all the possible bias, the present study supports the
claim that patients with stage 4 NB over the age of 1 year with a
tumour responding to initial intensive chemotherapy can benefit
from high-dose chemotherapy and haemopoietic stem cell rescue.
We are aware that this type of study is not the best way forward
and that important clinical questions should nowaday be answered
by randomised trials conducted on a multicentre basis with
international cooperation. Any chances of improving on the
clinical results will obviously come also from new insights on the
biology of neuroblastoma and the availability of new active
molecules.
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